Ident. | Authors (with country if any) | Title |
---|
000011 (2020) |
Binqing Fu ; Xiaoling Xu ; Haiming Wei | Why tocilizumab could be an effective treatment for severe COVID-19? |
000038 (2020) |
Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne] | Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. |
000042 (2020) |
Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis] | Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) |
000044 (2020) |
Ernest H. Choy [Royaume-Uni] ; Fabrizio De Benedetti [Italie] ; Tsutomu Takeuchi [Japon] ; Misato Hashizume [Japon] ; Markus R. John [Suisse] ; Tadamitsu Kishimoto [Japon] | Translating IL-6 biology into effective treatments |
000055 (2020) |
Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine] | Tocilizumab treatment in COVID-19: A single center experience. |
000071 (2020) |
Roos A W. Wennink [Pays-Bas] ; Viera Kalinina Ayuso [Pays-Bas] ; Lieuwe A. De Vries [Pays-Bas] ; Sebastiaan J. Vastert [Pays-Bas] ; Joke H. De Boer [Pays-Bas] | Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. |
000079 (2020) |
Caterina Vacchi [Italie] ; Marco Sebastiani [Italie] ; Giulia Cassone [Italie] ; Stefania Cerri [Italie] ; Giovanni Della Casa [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie] | Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review |
000082 (2020) |
Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud] | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
000084 (2020) |
Matthew Zirui Tay [Singapour] ; Chek Meng Poh [Singapour] ; Laurent Rénia [Singapour] ; Paul A. Macary [Singapour] ; Lisa F. P. Ng [Singapour, Royaume-Uni] | The trinity of COVID-19: immunity, inflammation and intervention |
000097 (2020) |
Weiyi Tan ; Jamil Aboulhosn | The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease |
000104 (2020) |
Wei Zhang [République populaire de Chine] ; Qiying Zhang [République populaire de Chine] ; Zihua Xuan [République populaire de Chine] ; Juan Liang [République populaire de Chine] ; Dongping Yang [République populaire de Chine] ; Meihuizi Ding [République populaire de Chine] ; Housheng Zhu [République populaire de Chine] ; Bo Su [République populaire de Chine] ; Xing Dai [République populaire de Chine] ; Xiaoyi Jia [République populaire de Chine] | The Protective Effect of Different Polar Solvent Extracts of Er Miao San on Rats with Adjuvant Arthritis |
000107 (2020) |
Kyung Eun Kim ; Suwon Jeon ; Jisun Song ; Tae Sung Kim ; Min Kyung Jung ; Myun Soo Kim ; Sunyoung Park ; Seung Beom Park ; Jeong Min Park ; Hyun Jeong Park [Corée du Sud] ; Daeho Cho | The Novel Synthetic Peptide AESIS-1 Exerts a Preventive Effect on Collagen-Induced Arthritis Mouse Model via STAT3 Suppression |
000129 (2020) |
Mariano Mora-Pereira [États-Unis] ; Eva M. Abarca [États-Unis] ; Sue Duran [États-Unis] ; William Ravis [États-Unis] ; Richard J. Mcmullen [États-Unis] ; Britta M. Fischer [États-Unis] ; Yann-Huei Phillip Lee [États-Unis] ; Anne A. Wooldridge [États-Unis] | Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies |
000134 (2020) |
Ayush Gupta [Inde] ; Narendra Kumar Bagri [Inde] ; Saroj Kumar Tripathy [Inde] ; Adarsh Barwad [Inde] ; Ravi Hari Phulware [Inde] ; Pankaj Hari [Inde] | Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis. |
000140 (2020) |
Yusho Ishii [Japon] ; Hiroshi Fujii [Japon] ; Koichiro Sugimura [Japon] ; Tsuyoshi Shirai [Japon] ; Yosuke Hoshi [Japon] ; Yoko Fujita [Japon] ; Yuko Shirota [Japon] ; Tomonori Ishii [Japon] ; Hiroaki Shimokawa [Japon] ; Hideo Harigae [Japon] | Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody |
000167 (2020) |
Peter A. Riedell ; Michael R. Bishop | Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas |
000187 (2020) |
Durga Prasanna Misra [Inde] ; Vikas Agarwal [Inde] ; Armen Yuri Gasparyan ; Olena Zimba [Ukraine] | Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |
000193 (2020) |
Ka-Tim Choy [République populaire de Chine] ; Alvina Yin-Lam Wong [République populaire de Chine] ; Prathanporn Kaewpreedee [République populaire de Chine] ; Sin Fun Sia [République populaire de Chine] ; Dongdong Chen [République populaire de Chine] ; Kenrie Pui Yan Hui [République populaire de Chine] ; Daniel Ka Wing Chu [République populaire de Chine] ; Michael Chi Wai Chan [République populaire de Chine] ; Peter Pak-Hang Cheung [République populaire de Chine] ; Xuhui Huang [République populaire de Chine] ; Malik Peiris [République populaire de Chine] ; Hui-Ling Yen [République populaire de Chine] | Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |
000199 (2020) |
Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis] | Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status |
000210 (2020) |
Thomas Koudstaal ; Karin A. Boomars ; Mirjam Kool | Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective |
000213 (2020) |
Ludivine Renaud [États-Unis] ; Willian A. Da Silveira [Royaume-Uni] ; Naoko Takamura [États-Unis] ; Gary Hardiman [États-Unis, Royaume-Uni] ; Carol Feghali-Bostwick [États-Unis] | Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis |